HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Caryl Antalis Selected Research

1,1,1,2,2- pentafluoro- 7- phenylheptan- 3- one

7/2011Combination therapy of an inhibitor of group VIA phospholipase A2 with paclitaxel is highly effective in blocking ovarian cancer development.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Caryl Antalis Research Topics

Disease

2Ovarian Epithelial Carcinoma
08/2012 - 07/2011
2Neoplasms (Cancer)
08/2012 - 07/2011
1Carcinogenesis
08/2012
1Ascites
08/2012
1Neoplasm Metastasis (Metastasis)
08/2012
1Ovarian Neoplasms (Ovarian Cancer)
07/2011
1Cardiac Sudden Death (Sudden Cardiac Arrest)
04/2008

Drug/Important Bio-Agent (IBA)

2Phospholipases (Phospholipase)IBA
08/2012 - 07/2011
2CalciumIBA
08/2012 - 07/2011
1methyl arachidonylfluorophosphonateIBA
08/2012
1EnzymesIBA
08/2012
1lysophosphatidic acidIBA
08/2012
11,1,1,2,2- pentafluoro- 7- phenylheptan- 3- oneIBA
07/2011
16- (bromomethylene)tetrahydro- 3- (1- naphthaleneyl)- 2H- pyran- 2- oneIBA
07/2011
1Phospholipases A2 (Phospholipase A2)IBA
07/2011
1Calcium-Independent Phospholipases A2IBA
07/2011
1Paclitaxel (Taxol)FDA LinkGeneric
07/2011
1Fatty Acids (Saturated Fatty Acids)IBA
04/2008

Therapy/Procedure

1Therapeutics
07/2011